Abstract:Objective: Somatostatin analogues have become the mainstay of the medical treatment of acromegaly. The aim of our study was to evaluate the efficacy and tolerability of octreotide-LAR (OCT-LAR) treatment in acromegalic patients. Design: Prospective open trial. Patients and methods: Eighty acromegalic patients (46 women; 18-80 years) were treated with OCT-LAR. Mean +/- SD duration of follow-up was 16.6 +/- 6.6 months (6-24 months). Twenty-eight patients received OCT-LAR as primary treatment. The target was to achieve normal IGF-I levels. Clinical activity was evaluated by symptom score and fasting samples for GH and IGF-I serum concentrations, obtained under basal conditions as well as during treatment. Pituitary tumour volume was assessed by magnetic resonance imaging of the sella. A tumour volume reduction of at least 25% was considered significant. Results: Clinical improvement was attained in most patients. Fifty-nine (74%) of them attained mean GH < 2.5 ng/ml and 33 (41%) achieved normal IGF-I by the 24th month of treatment. GH and IGF-I control increased throughout treatment. Regarding the 46 patients treated for at least 12 months there was a significant decrease of GH and IGF-I levels by the third month compared to basal levels, persisting with no subsequently variation. In the patient group that achieved normal serum IGF-1 during treatment (controlled group: n = 43) 20 patients maintained normal levels up to the latest follow-up, whereas 23 of them once again showed altered serum IGF-1-values of some measurements during follow-up, despite dose maintenance or elevation. Baseline percentage of the upper limit of IGF-I normal range, GH levels by the third month and length of treatment were predictive factors of IGF-I normalization. Tumour shrinkage occurred in 76% of primary patients. Among 21 diabetic patients, four worsened and five improved glycaemic control, based on glycated haemoglobin. One previously intolerant patient progressed to overt diabetes. Nine patients developed gall bladder sludge, other nine patients acquired microlithiasis and one patient developed gallstone pancreatitis. Conclusion: OCT-LAR is an effective agent in alleviating symptoms, suppressing GH, normalizing IGF-I and inducing tumour shrinkage in many acromegalic patients. Overall, OCT-LAR is well tolerated and should be recommended for nonsurgically cured acromegalics, and also be considered as primary therapy for selected cases, mainly for those with a low probability of surgical cure.

Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center

Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study

Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up

De-escalation treatment with pasireotide for acromegaly: a long-term experience

Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study

Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly

Pasireotide in the Personalized Treatment of Acromegaly

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY

Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis

Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review

Combined Therapy of Somatostatin Analogues with Pegvisomant for the Treatment of Acromegaly: a Meta-Analysis of Prospective Studies

Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study

Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study